{
    "root": "8af30ca1-ed3b-4775-806f-4fcc983548c5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Osmitrol",
    "value": "20241119",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        }
    ],
    "indications": "osmitrol indicated : • reduction intracranial pressure treatment cerebral edema ; • reduction elevated intraocular pressure .",
    "contraindications": "instructions ( 2.1 ) : • intravenous infusion preferably large central vein . • prior , evaluate renal , cardiac pulmonary status , correct fluid electrolyte imbalances . recommended ( 2.2 ) : • , concentration rate depend age , weight condition patient , including fluid requirement , urinary output concomitant therapy . • reduction intracranial pressure : 0.25 gram/kg administered every 6 8 hours intravenous infusion 30 minutes . • reduction intraocular pressure : 1.5 2 grams/kg 15 % 20 % w/v solution single dose administered intravenously least 30 minutes .",
    "warningsAndPrecautions": "osmitrol injection supplied single-dose , flexible viaflex plastic containers available follows : code size ( ml ) ndc product name 2d5613 500 0338-0353-03 10 % ( 0.1 g/ml mannitol , usp ) 2d5623 500 0338-0355-03 15 % ( 0.15 g/ml mannitol , usp ) 2d5632 250 0338-0357-02 20 % ( 0.2 g/ml mannitol , usp ) 2d5633 500 0338-0357-03 20 % ( 0.2 g/ml mannitol , usp ) remove container overwrap intended . exposure pharmaceutical products heat minimized . avoid excessive heat . store room temperature ( 25°c ) ; brief exposure 40°c adversely affect product .",
    "adverseReactions": "osmitrol contraindicated patients : • known hypersensitivity mannitol [ ( 5.1 ) ] • anuria [ ( 5.2 ) ] • severe hypovolemia [ ( 5.4 ) ] • pre-existing severe pulmonary vascular congestion pulmonary edema [ ( 5.5 ) ] • active intracranial bleeding except craniotomy",
    "indications_original": "OSMITROL is indicated for: \n                  \n                  \n                     \n                        •\n                        The reduction of intracranial pressure and treatment of cerebral edema;\n                     \n                     \n                        •\n                        The reduction of elevated intraocular pressure.",
    "contraindications_original": "Administration Instructions ( 2.1 ): • For intravenous infusion preferably into a large central vein. • Prior to administration, evaluate renal, cardiac and pulmonary status, and correct fluid and electrolyte imbalances. Recommended Dosage ( 2.2 ) : • The dosage, concentration and rate of administration depend on the age, weight and condition of the patient, including fluid requirement, urinary output and concomitant therapy. • Reduction of Intracranial Pressure : 0.25 gram/kg administered every 6 to 8 hours as an intravenous infusion over 30 minutes. • Reduction of Intraocular Pressure : 1.5 to 2 grams/kg of a 15% or 20% w/v solution as a single dose administered intravenously over at least 30 minutes.",
    "warningsAndPrecautions_original": "OSMITROL injection is supplied in single-dose, flexible VIAFLEX plastic containers and is available as follows: \n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Code\n                           \n                           \n                              Size (mL)\n                           \n                           \n                              NDC\n                           \n                           \n                              Product Name\n                           \n                        \n                        \n                           \n                              2D5613\n                           \n                           \n                              500\n                           \n                           \n                              0338-0353-03\n                           \n                           \n                              10% (0.1 g/mL mannitol, USP)\n                           \n                        \n                        \n                           \n                              2D5623\n                           \n                           \n                              500\n                           \n                           \n                              0338-0355-03\n                           \n                           \n                              15% (0.15 g/mL mannitol, USP)\n                           \n                        \n                        \n                           \n                              2D5632\n                           \n                           \n                              250\n                           \n                           \n                              0338-0357-02\n                           \n                           \n                              20% (0.2 g/mL mannitol, USP)\n                           \n                        \n                        \n                           \n                              2D5633\n                           \n                           \n                              500\n                           \n                           \n                              0338-0357-03\n                           \n                           \n                              20% (0.2 g/mL mannitol, USP)\n                           \n                        \n                     \n                  \n                  Do not remove container from overwrap until intended for use.\n                  Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Store at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.",
    "adverseReactions_original": "OSMITROL is contraindicated in patients with: \n                  \n                  \n                     \n                        •\n                        Known hypersensitivity to mannitol [see Warnings and Precautions (5.1)]\n                     \n                     \n                        •\n                        Anuria [see Warnings and Precautions (5.2)]\n                     \n                     \n                        •\n                        Severe hypovolemia [see Warnings and Precautions (5.4)]\n                     \n                     \n                        •\n                        Pre-existing severe pulmonary vascular congestion or pulmonary edema [see Warnings and Precautions (5.5)]\n                     \n                     \n                        •\n                        Active intracranial bleeding except during craniotomy"
}